Medications

Gilead buys US pharma rival Pharmasset

US biotech firm Gilead Sciences announced plans Monday to acquire rival Pharmasset, a group specializing in treatments for AIDS and hepatitis, for $11 billion.

Diseases, Conditions, Syndromes

Danger signal limits Hepatitis C infection

Despite the fact that hepatitis C virus (HCV) persists chronically in about 80 percent of those infected, some liver cells remain free of the virus even after many years. Now Sung Key Jang of Pohang University of Science ...

Diseases, Conditions, Syndromes

How hepatitis C virus evades the immune system

Hepatitis C virus (HCV) may cause chronic infection to the liver, which can result in irreversible liver damage and liver cancer. How HCV manages to evade the immune system to infect the host chronically is not entirely understood. ...

Diseases, Conditions, Syndromes

New strains of hepatitis C found in Africa

The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa. The research from the Wellcome Sanger Institute, the MRC-University ...

Medications

DAAs cut deaths in those treated for HCV-related liver cancer

(HealthDay)—Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the ...

Diseases, Conditions, Syndromes

The ABCDEs of viral hepatitis

Millions of people across the globe, including in our own backyard, are living with a viral hepatitis infection and may not even know it. Experts at Baylor College of Medicine say awareness and diagnosis is the first step ...

page 6 from 30